Genetic counseling

CancerIQ Unveils New Service Offerings and Integrated Risk Score Calculator at NCoBC 2023

Retrieved on: 
Friday, March 24, 2023

CHICAGO, March 24, 2023 /PRNewswire-PRWeb/ -- CancerIQ will showcase its latest precision cancer prevention and early detection offerings for breast centers at the 32nd Annual Interdisciplinary Breast Center Conference (NCoBC 2023) in Las Vegas, March 24-28, (Booth #301). The company will offer NCoBC attendees an exclusive first look at two exciting new offerings: CancerIQ Complete, the industry's first full-service suite designed to help breast centers start, run and grow high-risk breast programs; and a new real-time, EHR-initiated CancerIQ Risk Calculator.

Key Points: 
  • The company will offer NCoBC attendees an exclusive first look at two exciting new offerings: CancerIQ Complete, the industry's first full-service suite designed to help breast centers start, run and grow high-risk breast programs; and a new real-time, EHR-initiated CancerIQ Risk Calculator.
  • CancerIQ helps providers traverse the challenges of managing population-wide cancer risk assessment to offer more personalized, evidence-based care pathways that lead to early cancer detection and prevention.
  • The new Risk Score Calculator brings comprehensive risk assessment into leading EHR workflows.
  • CancerIQ is proudly sponsoring the High Risk IT Forum in the Pre-Conference High Risk Breast Program: Essentials for Success.

Baptist Cancer Center research proves incidental lung nodule program effective in detecting cancer early

Retrieved on: 
Thursday, March 9, 2023

Memphis, TN, March 09, 2023 (GLOBE NEWSWIRE) -- Memphis-based Baptist Cancer Center published a JAMA Network Open article proving the effectiveness of incidental lung nodule, or tumor, programs in detecting lung cancer early.

Key Points: 
  • Memphis, TN, March 09, 2023 (GLOBE NEWSWIRE) -- Memphis-based Baptist Cancer Center published a JAMA Network Open article proving the effectiveness of incidental lung nodule, or tumor, programs in detecting lung cancer early.
  • Those in the lung nodule program had significantly greater incidence of lung cancer diagnosis within two years.
  • These findings suggest that lung nodule program participants, regardless of smoking history, had a substantial risk for lung cancer.
  • Baptist Memorial Health Care Foundation awarded a $1 million grant to Baptist Cancer Center in August 2020 to fund the incidental nodule research project.

Mount Sinai Expert Urge Colon Cancer Awareness and Education to Reverse Decline in Screening Rates during Pandemic

Retrieved on: 
Wednesday, March 1, 2023

NEW YORK, March 1, 2023 /PRNewswire-PRWeb/ -- Colorectal cancer is the second leading cause of cancer deaths in both men and women in the United States. Although highly treatable and preventable, about 140,000 Americans are diagnosed and more than 50,000 people die each year, according to the Centers for Disease Control and Prevention (CDC). The United States Preventative Task Force recommends starting age of screening from 45 to 50.

Key Points: 
  • NEW YORK, March 1, 2023 /PRNewswire-PRWeb/ -- Colorectal cancer is the second leading cause of cancer deaths in both men and women in the United States.
  • In an effort to increase awareness and screening, Mount Sinai has expanded Colorectal Cancer Awareness Initiatives across all eight hospital sites during the month of March to provide patients with access to health professionals to discuss prevention, screening options, and risk factors.
  • However, colorectal cancer disproportionately affects the Black community, where the rates are the highest of any racial/ethnic group in the US.
  • African Americans are 20% more likely to get colorectal cancer and about 40% more likely to die from colorectal cancer than most other groups.

Detroit Pistons Become First Professional Sports Team in the United States to Partner with Progyny to Provide Comprehensive, Value-Based Family Building Care

Retrieved on: 
Wednesday, March 1, 2023

Through this partnership, the Detroit Pistons will have access to equitable and comprehensive family building care that its diverse workforce requires.

Key Points: 
  • Through this partnership, the Detroit Pistons will have access to equitable and comprehensive family building care that its diverse workforce requires.
  • The Detroit Pistons are committed to fostering a cohesive and equitable benefits plan that puts the needs of its employees first.
  • In addition to these services, the Detroit Pistons sponsor an adoption and surrogacy program to ensure that regardless of their path to parenthood, their team is supported.
  • “When considering options for a family building benefits solution, we prioritized one that would meet the varied needs of our employees.

Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC

Retrieved on: 
Wednesday, March 1, 2023

SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the first evidence-based expanded carrier screening (ECS) practice guidelines for reproductive risk assessment published by the National Society of Genetic Counselors (NSGC) in the Journal of Genetic Counseling.

Key Points: 
  • SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the first evidence-based expanded carrier screening (ECS) practice guidelines for reproductive risk assessment published by the National Society of Genetic Counselors (NSGC) in the Journal of Genetic Counseling.
  • Myriad’s Dale Muzzey, chief scientific officer; Katie Johansen Taber, VP, clinical product research and partnerships; and Gabriel Lazarin, VP of Medical Affairs for Women’s Health, share their perspectives on the impact of the guidelines in the video below and on Myriad’s YouTube channel.

BioAro Unveils Its Targeted Cardiac Panel for Patients Facing the Risk of Heart Failure During the Peak of Heart Month

Retrieved on: 
Monday, February 20, 2023

Calgary, Alberta--(Newsfile Corp. - February 20, 2023) - Canada-based biotechnology company BioAro announces the unveiling of its new targeted cardiac panel for patients who face the potential risks of heart failure.

Key Points: 
  • Calgary, Alberta--(Newsfile Corp. - February 20, 2023) - Canada-based biotechnology company BioAro announces the unveiling of its new targeted cardiac panel for patients who face the potential risks of heart failure.
  • Almost 1 in 3 Canadians are touched by heart failure, and over 100,000 Canadians get diagnosed with a new diagnosis of heart failure every year.
  • The launch also seeks to raise awareness of various heart diseases, as part of international heart month in February 2023.
  • BioAro promotes this month to take extra care of heart health and help reduce the mortality rate due to heart diseases.

U.S. Carrier Screening Market to Reach USD 2.14 Billion, by 2031 at 14.4% CAGR: Allied Market Research

Retrieved on: 
Tuesday, February 14, 2023

PORTLAND, Ore., Feb. 14, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "U.S. carrier screening Market by Type (Expanded Carrier Screening and Targeted Disease Carrier Screening), by Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays and Others), by End User (Hospitals & Clinics, Reference Laboratories, Physician Offices and Others): Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the U.S. carrier screening industry generated $585.46 million in 2021, and is estimated to reach $2.14 billion by 2031, witnessing a CAGR of 14.4% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscapes, and competitive scenarios.

Key Points: 
  • PORTLAND, Ore., Feb. 14, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, " U.S. carrier screening Market by Type (Expanded Carrier Screening and Targeted Disease Carrier Screening), by Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays and Others), by End User (Hospitals & Clinics, Reference Laboratories, Physician Offices and Others): Opportunity Analysis and Industry Forecast, 2021-2031."
  • According to the report, the U.S. carrier screening industry generated $585.46 million in 2021, and is estimated to reach $2.14 billion by 2031, witnessing a CAGR of 14.4% from 2022 to 2031.
  • By type, the expanded carrier screening segment held the major share in 2021, accounting for more than two-fifths of the U.S. carrier screening market revenue.
  • By technology, the DNA sequencing segment accounted for the highest revenue in 2021, contributing to nearly two-fifths of the U.S. carrier screening market share.

U.S. Carrier Screening Market to Reach USD 2.14 Billion, by 2031 at 14.4% CAGR: Allied Market Research

Retrieved on: 
Tuesday, February 14, 2023

PORTLAND, Ore., Feb. 14, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "U.S. carrier screening Market by Type (Expanded Carrier Screening and Targeted Disease Carrier Screening), by Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays and Others), by End User (Hospitals & Clinics, Reference Laboratories, Physician Offices and Others): Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the U.S. carrier screening industry generated $585.46 million in 2021, and is estimated to reach $2.14 billion by 2031, witnessing a CAGR of 14.4% from 2022 to 2031. The report offers a detailed analysis of changing market trends, top segments, key investment pockets, value chains, regional landscapes, and competitive scenarios.

Key Points: 
  • PORTLAND, Ore., Feb. 14, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, " U.S. carrier screening Market by Type (Expanded Carrier Screening and Targeted Disease Carrier Screening), by Technology (DNA Sequencing, Polymerase Chain Reaction, Microarrays and Others), by End User (Hospitals & Clinics, Reference Laboratories, Physician Offices and Others): Opportunity Analysis and Industry Forecast, 2021-2031."
  • According to the report, the U.S. carrier screening industry generated $585.46 million in 2021, and is estimated to reach $2.14 billion by 2031, witnessing a CAGR of 14.4% from 2022 to 2031.
  • By type, the expanded carrier screening segment held the major share in 2021, accounting for more than two-fifths of the U.S. carrier screening market revenue.
  • By technology, the DNA sequencing segment accounted for the highest revenue in 2021, contributing to nearly two-fifths of the U.S. carrier screening market share.

Latest Information about Medication Safety in Breastmilk Now Easily Accessible via New LactRx App

Retrieved on: 
Wednesday, February 8, 2023

BRENTWOOD, Tenn., Feb. 8, 2023 /PRNewswire-PRWeb/ -- The non-profit Organization of Teratology Information Specialists (OTIS), through its public-facing service known as MotherToBaby, launches LactRx, a free app providing current information on the use of medications, vaccines, diagnostic agents & drugs of misuse during breastfeeding. The LactRx app provides easy access to the LactMed database, a resource from the National Library of Medicine (NLM).

Key Points: 
  • The LactRx app provides easy access to the LactMed database, a resource from the National Library of Medicine (NLM).
  • Because of this, she saw it as an opportunity for MotherToBaby to help build and host a new app with all of the LactMed information.
  • "The NLM made the decision to continue supporting web access to LactMed, and to discontinue support for its app.
  • Information presented in the LactRx app is not intended to be a substitute for professional judgment.

Global Genes Announces Completion of RARE-X Merger and Strategic Direction for Combined Organization

Retrieved on: 
Tuesday, February 7, 2023

ALISO VIEJO, Calif., Feb. 7, 2023 /PRNewswire-PRWeb/ -- The rare disease patient advocacy organization Global Genes today announced it has completed its merger with the nonprofit data-sharing platform RARE-X and unveiled a three-pronged strategy for the combined organization that focuses on providing tools, connections, and opportunities to meet the needs of next-generation advocacy.

Key Points: 
  • Son Rigby said going forward, Global Genes is organizing its work around three pillars: support for patients and developing communities, educational tools, and research enablement.
  • Global Genes has a rich history of providing education and information through its toolkits, events, webinars, podcasts, and videos.
  • To help patients better address mental health issues, Global Genes is working to connect people with the most appropriate resources faster.
  • To support diversity in research, Global Genes is launching two pilot programs with partners in the Kansas City and Alabama regions.